Hangzhou Tigermed FY26 interim net profit turns to loss of RMB 413.2 million; revenue rises 14.1% to RMB 3.71 billion

• Hangzhou Tigermed posted revenue of RMB 3.71 billion for the six months ended June 30, 2026, up 14.1% year over year.
• Net profit attributable to owners swung to a loss of RMB 413.2 million from profit a year earlier; basic EPS turned to RMB -0.48.
• Gross profit rose 4.3% to RMB 1.02 billion, while gross margin fell 2.6 percentage points to 27.5%.
• CTS segment revenue climbed 20.7% to RMB 1.77 billion, while CRLS increased 8.6% to RMB 1.93 billion.
• Management cited a RMB 443.3 million fair-value loss, including RMB 719.3 million tied to PegBio, and declared no interim dividend.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Tigermed Consulting Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260925-12346801), on September 25, 2026, and is solely responsible for the information contained therein.